Cellectis will host an Investor R&D Day in New York City on October 16, 2025, presenting Phase 1 dataset and late-stage development strategy for lasme-cel. End-of-Phase 1 meetings with FDA & EMA for lasme-cel completed in July 2025. Servier arbitration decision expected by December 15, 2025. Cash reserves of $230 million as of June 30, 2025, to fund operations into H2 2027.

In pipeline news, a Phase 1 study of eti-cel in r/r NHL is ongoing, with readout expected in late 2025. AstraZeneca partnership R&D activities continue to advance for three programs initiated. Appointment of André Muller to Cellectis’ Board of Directors. Conference call and webcast scheduled for August 5, 2025, at 8:00AM ET / 2:00PM CET.

Regarding partnerships, Servier arbitration proceedings are ongoing, with a decision expected by December 15, 2025. Allogene’s ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma has reached milestones. Allogene presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma.

Financially, Cellectis had $230 million in cash, cash equivalents, and fixed-term deposits as of June 30, 2025. Revenues and other income for the six-month period ended June 30, 2025, were $30.2 million. Net loss attributable to shareholders was $41.9 million for the same period. Adjusted net loss attributable to shareholders was $39.6 million.

Cellectis is a clinical-stage biotech company developing gene-editing cell and gene therapies. The company’s focus includes CAR T immunotherapies in oncology and gene therapies in other indications. Cellectis is listed on the Nasdaq Global Market and Euronext Growth. For more information, visit their website or follow them on LinkedIn.

Read more at GlobeNewswire: Cellectis Reports Second Quarter 2025 Financial Results &